EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor–naïve patients with metastatic uveal melanoma

J.J. Sacco, J.C. Moser, A.N. Shoushtari, A. Betof, D. Davar, S. Chandra, A. Ikeguchi, A.K. Salama, R.J. Sullivan, S. Khan, S.P. Patel, A.M. Joshua und 6 weitere

EJC Skin Cancer · 2026 · 4 · 100792

DOI: 10.1016/j.ejcskn.2026.100792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EJC Skin Cancer, 2026. Verfasst von J.J. Sacco und 17 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Sacco, J., Moser, J., Shoushtari, A., Betof, A., Davar, D., Chandra, S., Ikeguchi, A., Salama, A., Sullivan, R., Khan, S., Patel, S., Joshua, A., Hassel, J., Agbaje-Williams, M., Navarro, M., Marpadga, R., Gullo, G., & Orloff, M. (2026). A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor–naïve patients with metastatic uveal melanoma. EJC Skin Cancer, 4, 100792. https://doi.org/10.1016/j.ejcskn.2026.100792

Vancouver

Sacco J, Moser J, Shoushtari A, Betof A, Davar D, Chandra S, et al. A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor–naïve patients with metastatic uveal melanoma. EJC Skin Cancer. 2026;4:100792. doi:10.1016/j.ejcskn.2026.100792

BibTeX
@article{Sacco2026,
  author = {Sacco, J.J. and Moser, J.C. and Shoushtari, A.N. and Betof, A. and Davar, D. and Chandra, S. and Ikeguchi, A. and Salama, A.K. and Sullivan, R.J. and Khan, S. and Patel, S.P. and Joshua, A.M. and Hassel, J.C. and Agbaje-Williams, M. and Navarro, M. and Marpadga, R. and Gullo, G. and Orloff, M.M.},
  title = {A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor–naïve patients with metastatic uveal melanoma},
  journal = {EJC Skin Cancer},
  year = {2026},
  volume = {4},
  pages = {100792},
  doi = {10.1016/j.ejcskn.2026.100792}
}
Kostenlos starten →